Fusen Pharmaceutical Company Limited (SEHK: 1652)
Health Care · Pharmaceuticals · CN
HK$0.96
-7.69% today · +174.3% 1Y
Fusen Pharmaceutical Company Limited (SEHK: 1652) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $90.53M and employs 1,005 people.
Over the last twelve months the share price has gained 174.3%, trading between 0.32 and 1.75.
Tweenvest scores Fusen Pharmaceutical Company Limited across four factors: quality 62/100, value 34/100, growth 0/100. Its strongest factor is quality.
1652 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $90.53M
- Revenue (TTM)
- $39.08M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- HK$1.75
- 52-week low
- HK$0.32
- Avg volume (3M)
- —
- Shares outstanding
- 739.30M
- Employees
- 1,005
- Next earnings
- —
About Fusen Pharmaceutical Company Limited
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.
- ISIN
- KYG370981030
- Founded
- 2003
- Listed since
- Jul 11, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,232.30 | -1.17% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.64 | -0.15% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.40 | +3.81% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.52 | +1.97% |
Figures last refreshed Aug 18, 2026.